

Lecicarbon A suppositories for the management of chronic constipation

NHS Devon

Commissioning policy

The routine commissioning of leccicarbon A suppositories for the management of chronic constipation is accepted in Devon.

The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Lecicarbon A suppositories act by releasing carbon dioxide on insertion into the rectum which stimulates bowel evacuation. Lecicarbon A suppositories were licensed in the UK through a route which recognises products of established use in other European Union countries. The clinical evidence suggests that approximately 50% of patients achieve bowel evacuation after insertion of a suppository.

A trial of leccicarbon A suppositories would be considered as an alternative to options, such as rectal irrigation, in patients for whom conservative management and the use of other established laxatives were not effective. Taking into account place in therapy, acquisition cost and alternative treatment options, leccicarbon A suppositories are considered to offer value for money.

Guidance notes on exceptionality

This general policy does not replace clinical judgement on the appropriate treatment of an individual patient.

Date of publication:	Version:
21.07.2017	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG Policy adopted by NHS Devon CCG on 01.04.2019 Policy adopted by NHS Devon ICB on 01.07.2022